These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2014 related items for PubMed ID: 30029909

  • 1. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 2. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD, Lynch JB.
    Drug Des Devel Ther; 2015 Jul; 9():677-82. PubMed ID: 25678771
    [Abstract] [Full Text] [Related]

  • 3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 4. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS, Jeong BH, Koh WJ.
    Expert Opin Pharmacother; 2015 Feb 16; 16(2):253-61. PubMed ID: 25327169
    [Abstract] [Full Text] [Related]

  • 5. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA, Scott LJ.
    Drugs; 2015 Jan 16; 75(1):91-100. PubMed ID: 25404020
    [Abstract] [Full Text] [Related]

  • 6. Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis.
    Chen X, Hashizume H, Tomishige T, Nakamura I, Matsuba M, Fujiwara M, Kitamoto R, Hanaki E, Ohba Y, Matsumoto M.
    Antimicrob Agents Chemother; 2017 Jun 16; 61(6):. PubMed ID: 28373190
    [Abstract] [Full Text] [Related]

  • 7. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.
    N Engl J Med; 2012 Jun 07; 366(23):2151-60. PubMed ID: 22670901
    [Abstract] [Full Text] [Related]

  • 8. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R, Soni I, Dasgupta A, Chopra S.
    Drugs Today (Barc); 2015 Feb 07; 51(2):117-23. PubMed ID: 25756067
    [Abstract] [Full Text] [Related]

  • 9. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J, Kang H, Hwang SH, Park JS, Kang B, Lee T, Koh WJ, Yim JJ, Jeon D.
    J Antimicrob Chemother; 2018 Feb 01; 73(2):503-508. PubMed ID: 29069496
    [Abstract] [Full Text] [Related]

  • 10. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Curr Opin Pulm Med; 2018 May 01; 24(3):244-252. PubMed ID: 29470252
    [Abstract] [Full Text] [Related]

  • 11. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
    Zhang Q, Liu Y, Tang S, Sha W, Xiao H.
    Cell Biochem Biophys; 2013 May 01; 67(3):957-63. PubMed ID: 23546935
    [Abstract] [Full Text] [Related]

  • 12. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, Shashkina E, Kreiswirth BN, Liu Y, Matsumoto M, Geiter L.
    Antimicrob Agents Chemother; 2016 Jun 01; 60(6):3316-22. PubMed ID: 26976868
    [Abstract] [Full Text] [Related]

  • 13. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.
    Int J Tuberc Lung Dis; 2016 Feb 01; 20(2):177-86. PubMed ID: 26792469
    [Abstract] [Full Text] [Related]

  • 14. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.
    Int J Mol Sci; 2017 Feb 07; 18(2):. PubMed ID: 28178199
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.
    Lancet Respir Med; 2019 Mar 07; 7(3):249-259. PubMed ID: 30630778
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y, Mathema B, Zhao Q, Zheng X, Li D, Jiang W, Wang W, Xu B.
    Tuberculosis (Edinb); 2016 Mar 08; 97():18-25. PubMed ID: 26980491
    [Abstract] [Full Text] [Related]

  • 18. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 08; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 19. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS, Kim KJ, Choi H, Lee SH.
    Ann Lab Med; 2018 Nov 08; 38(6):563-568. PubMed ID: 30027700
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
    Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Subay S, Adiono SH.
    Int J Mycobacteriol; 2024 Apr 01; 13(2):140-146. PubMed ID: 38916383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 101.